Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities

Journal of Medical Economics

Volumn 17, Issue 4, 2014, Pages 288-295

  Truong, H L ^a   Nellesen, D ^a   Ludlam, W H ^b   Neary, M P ^b  

^a ANALYSIS GROUP   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Budget impact; Cushing's disease; Orphan disease

Indexed keywords

CABERGOLINE; KETOCONAZOLE; MIFEPRISTONE; MITOTANE; PASIREOTIDE; SOMATOSTATIN;

ADRENALECTOMY; ARTICLE; BUDGET; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; CUSHING DISEASE; DRUG APPROVAL; DRUG COST; ENDOMETRIAL DISEASE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; LIQUORRHEA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL FEE; MENINGITIS; NELSON SYNDROME; OFF LABEL DRUG USE; PATIENT MONITORING; PHARMACEUTICAL CARE; POSTOPERATIVE COMPLICATION; RADIATION INJURY; RADIOSURGERY; RADIOTHERAPY; REIMBURSEMENT; REOPERATION; SENSITIVITY ANALYSIS; THROMBOSIS; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; COMPLICATION; COST; ECONOMICS; HEALTH SERVICE; PITUITARY ACTH HYPERSECRETION; STATISTICAL MODEL; UTILIZATION;

COMORBIDITY; COSTS AND COST ANALYSIS; HEALTH SERVICES; HUMANS; MODELS, ECONOMIC; PITUITARY ACTH HYPERSECRETION; SOMATOSTATIN;

EID: 84898999378     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.877470     Document Type: Article

References (50)

1. Orth DN. Cushing's syndrome. N Engl J Med 1995;332:791-803
2. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropindependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62
3. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012;167:311-26
4. Arnaldi G, Boscaro M. New treatment guidelines on Cushing's disease. F1000 Med Rep 2009;1:64. doi:10.3410/M1-64
5. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-602
6. Burton T, Rey G, Neary M, et al. Development of an algorithm to identify Cushing's disease patients in a US administrative claims database. Poster presented at: The 13th International Pituitary Congress, San Francisco, CA. June 12-14, 2013
7. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in stoke-on-Trent, UK: Audit and metaanalysis of literature. J Clin Endocrinol Metab 2011;96:632-42
8. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease. Clin Endocrinol (Oxf) 1994;40:479-84
9. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117-23
10. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75
11. Broder M, Neary M, Chang E, et al. Incidence of Cushing's disease in the United States. Poster presented at: The 95th Annual Meeting of the Endocrine Society, San Francisco, CA. June 15-18, 2013
12. Patel D, Stephens J, Wiegand P, et al. Reduction in comorbidities and cost savings associated with biochemical control in patients with Cushing's disease: a literature-based analysis. Poster presented at: The ISPOR 14th Annual European Congress, Madrid, Spain. November 5-8, 2011
13. Swearingen B, Wu N, Chen S, et al. Healthcare resource use and costs among patients with Cushing's disease. Endocr Pract 2011;17:681-90
14. Feelders R, Forsythe A, Stemmer V, et al. Burden of Cushing's disease-A retrospective chart audit. Poster presented at: The European NeuoEndocrine Association, Vienna, Austria. September 15-17, 2012
15. Gotch PM. Cushing's syndrome from the patient's perspective. Endocrinol Metab Clin North Am 1994;23:607-17
16. Clayton RN. Mortality in Cushing's Disease. Neuroendocrinology 2010;92(Suppl 1):71-6
17. Pereira AM, Tiemensma J, Romijn JA, Biermasz NR. Cognitive impairment and psychopathology in patients with pituitary diseases. Neth J Med 2012;70:255-60
18. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 2009;1179:41-55
19. Fietta P, Fietta P, Delsante G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci 2009;63:613-22
20. van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab 2005;90:3279-86
21. Alcalar N, Ozkan S, Kadioglu P, et al. Evaluation of depression, quality of life and body image in patients with Cushing's disease. Pituitary 2012;16:333-40
22. Wagenmakers MAEM, Netea-Maier RT, Prins JB, et al. Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur J Endocrinol 2012;167:687-95
23. Keil MF, Merke DP, Gandhi R, et al. Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study. Clin Endocrinol (Oxf) 2009;71:326-33
24. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40
25. Broder M, Neary M, Chang E, et al. Annual economic burden associated with Cushing's disease in the United States. Poster presented at: The 95th Annual Meeting of the Endocrine Society, San Francisco, CA. 15-18 June, 2013
26. Brown RL, Weiss RE. An approach to the evaluation and treatment of Cushing's disease. Expert Rev Anticancer Ther 2006;6(Suppl 9):S37-S46
27. Alwani RA, de Herder WW, van Aken MO, et al. Biochemical predictors of outcome of pituitary surgery for Cushing's disease. Neuroendocrinology 2010;91:169-78
28. Corcept Therapeutics Incorporated. Korlym [package insert]. 2012. Menlo Park, CA
29. Broder M, Neary M, Chang E, et al. Real-world treatment patterns in Cushing's disease patients in two large US nationwide databases: application of novel, graphical methodology. Poster presented at: The 95th Annual Meeting of the Endocrine Society, San Francisco, CA. June 15-18, 2013
30. Food and Drug Administration (FDA). FDA Approved Drug Products. 2013 [cited 2013 Dec 16]; Available from: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails
31. Bureau of Labor Statustics UDoL. Consumer Price Index (CPI) for Medical Care Services (CUSR0000SAM2). 2013 [cited 2013 Jul 16]; Available from: http://www.bls.gov/cpi/
32. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007;10:336-47
33. Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 2010;92(Suppl 1):111-5
34. Patel DA, Maldonado M, Stephens JM, et al. Cost of second line non-pharmacologic interventions and their related complications in Cushing's disease: a literature-based economic analysis. Poster presented at: The 12th Annual International Pituitary Congress, Boston, MA. June 1-3, 2011
35. Agency for Healthcare Research & Quality (AHRQ). Healthcare Cost and Utilization Project (HCUP). [cited 2012 Dec 16]; Available from: http://www.ahrq.gov/research/data/hcup/index.html
36. Novartis Pharmaceuticals Corp. Signifor [package insert]. 2012. East Hanover, NJ
37. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009;94:223-30
38. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012;97:2039-49
39. Thomson Reuters. ReadyPrice Online. RedBook 2013 [cited 2013 Jul 11]; Available from: http://www.thomsonhc.com/micromedex2/librarian
40. Colao A, Petersenn S, Newell-Price J, et al. A 12-month Phase III study of pasireotide in Cushing's disease. N Engl J Med 2012;366:914-24
41. Lila AR, Gopal RA, Acharya SV, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 2010;16:968-76
42. Moncet D, Morando DJ, Pitoia F, et al. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome. Medicina (B Aires) 2007;67:26-31
43. Castinetti F, Nagai M, Dufour H, et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 2007;156:91-8
44. Ding XF, Li HZ, Yan WG, et al. Role of adrenalectomy in recurrent Cushing's disease. Chin Med J 2010;123:1658-62
45. Rollin GF, Ferreira NP, Czepielewski MAl. Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing's disease. Arq Bras Endocrinol Metabol 2007;51:1355-61
46. Barber TM, Adams E, Ansorge O, et al. Nelson's syndrome. Eur J Endocrinol 2010;163:495-507
47. Truong H, Nellesen D, Neary M, Ludlam W. Economic burden of multiple chronic comorbidities associated with Cushing's Disease, a rare endocrine disorder. Poster presented at: The DIA/NORD US Conference on Rare Diseases and Orphan Products: The New Era in Health Care, Bethesda, MD. October 7-9, 2013
48. Truong HL, Nellesen D, Ludlam W, Neary M. Budget Impact of Signifor (Pasireotide) for the Treatment of Cushing's Disease, a rare endocrine disorder associated with considerable comorbidities. Poster presented at: The AMCP Nexus Conference: Connecting Health Care and Innovation, San Antonio, TX. October 14-18, 2013
49. Medi-Span. Medi-Span Price Rx. Medi-Span 2013 [cited 2013 Mar 15]; Available from: https://pricerx.medispan.com/
50. First Databank (FDB). First Databank (FDB) 2013 [cited 2013 Mar 13]; Available from: http://www.fdbhealth.com/